This case report describes a boy aged 2 years 11 months with a thoracic mass initially thought to be embryonal rhabdomyosarcoma. After initial therapy and surgery, the final diagnosis was pleuropulmonary blastoma, type III, and genetic testing found a pathogenic DICER1 variant.
The child received several chemotherapy drugs, including vincristine, actinomycin, cyclophosphamide, doxorubicin, and dacarbazine, and experienced severe cytopenias as a side effect. The report notes that adequate tissue sampling, expert pathology review, and early molecular testing were valuable in reaching the correct diagnosis.
Because this is a single case, the findings are not generalizable. It shows how a diagnosis can change with more information, but it does not prove a specific treatment works for everyone.
Readers should understand that pleuropulmonary blastoma should be considered in children with aggressive thoracic masses, and that genetic testing can guide care, but this report alone does not change standard practice.